Dutch-based biotech, Prosensa researchers work on developing, possibly the World's first treatment for Duchenne muscular dystrophy disease (DMD) at their new laboratory in Leiden February 17, 2011. Prosensa is one of a new wave of successful biotechs that are emerging, many of them in the Benelux and Scandinavia, and stepping over a past generation of biotech casualties. The biotech focuses on a rare disease, a new hot area for large pharma increasingly facing drug patent expiries, and there is now resurgent industry talk of stock listings and trade sales. Prosensa and its partner, Britain's GlaxoSmithKline, started a phase III clinical study into a potential treatment last month, the most advanced ongoing study into (DMD), building hopes for patients and investors alike. To match ANALYSIS BIOTECHNOLOGY-EUROPE/ REUTERS/Jerry Lampen (NETHERLANDS - Tags: POLITICS EDUCATION SCI TECH SOCIETY)